Fox Chase Cancer Center News

PHILADELPHIA (December 29, 2020) – Researchers at Fox Chase Cancer Center recently published a study outlining the center’s 30 years of experience with a rare form of pancreatic cancer.

PHILADELPHIA (December 28, 2020)–Researchers at Fox Chase Cancer Center have identified a potential new target, a tyrosine kinase known as Wee1, for the treatment of gastrointestinal stromal tumor (GIST).

PHILADELPHIA (December 23, 2020)—Researchers at Fox Chase Cancer Center have published research showing that perceiving positive life changes, known as “benefit finding,” is common among colorectal cancer (CRC) patients, especially women and racial minorities. Benefit finding is thought to promote better adjustment after cancer, yet is poorly understood in colorectal cancer.

PHILADELPHIA (December 16, 2020)—A team of scientists from Fox Chase Cancer Center received a pilot award from the Melanoma Research Alliance (MRA) for a research project that will investigate a new drug target for the treatment of melanoma that combines aspects of epigenetics and immunotherapy.

PHILADELPHIA (December 8, 2020) – Researchers from Fox Chase Cancer Center have recently publish a series of collaborative studies that could help facilitate the development of new therapeutic agents for cancer treatment by altering integrin activity.

PHILADELPHIA (December 7, 2020)—Namrata (Neena) Vijayvergia, MD, assistant chief of gastrointestinal medical oncology at Fox Chase Cancer Center, was recently named a 2020 recipient of the 40 Under 40 in Cancer Award.

PHILADELPHIA (December 7, 2020) – Y. Lynn Wang, MD, PhD, FACP, a professor in the Department of Pathology and Blood Cell Development and Function program at Fox Chase Cancer Center, recently published a comprehensive review of molecular biomarkers in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States.

PHILADELPHIA (December 3, 2020)—Researchers at Fox Chase Cancer Center recently published new data showing that patients with head and neck cancer (HNC) recur just weeks after a complete operation at an under-appreciated rate and that this is associated with poor survival outcomes.